Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P07585

UPID:
PGS2_HUMAN

ALTERNATIVE NAMES:
Bone proteoglycan II; PG-S2; PG40

ALTERNATIVE UPACC:
P07585; Q9P0Z0; Q9P0Z1; Q9Y5N8; Q9Y5N9

BACKGROUND:
Decorin, also referred to as Bone proteoglycan II, PG-S2, or PG40, is a key player in connective tissue architecture. Its primary function is to modulate the formation of collagen fibrils, which are essential for maintaining the structural integrity of tissues. The protein, identified by the unique identifier P07585, is a critical component of the extracellular matrix, influencing tissue development and repair.

THERAPEUTIC SIGNIFICANCE:
Given Decorin's critical role in congenital stromal corneal dystrophy, a condition marked by early-onset corneal clouding and visual impairment, its study offers promising avenues for therapeutic intervention. By elucidating the mechanisms by which Decorin influences corneal structure and function, researchers can pave the way for innovative treatments that restore vision and improve quality of life for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.